Isis Pharmaceuticals Announces Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx

Isis Pharmaceuticals

announced new results from its Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with very high to severely high triglycerides.   These new data and an overall summary of the Phase 2 program for ISIS-APOCIIIRx were presented today by Dr. Rosanne Crooke at the American Heart Association Scientific Sessions in Dallas.  In the Phase 2 study, patients with very high to severely high triglyceride levels were treated with ISIS-APOCIIIRx as a monotherapy and achieved statistically significant mean reductions of up to 80 percent in apolipoprotein C-III (apoC-III) and up to 71 percent in triglycerides.  In addition, patients treated with ISIS-APOCIIIRx achieved statistically significant mean increases of up to 46 percent in high-density lipoprotein cholesterol (HDL-C).   These data are consistent with the interim analysis reported in August of this year.   These new data also demonstrated that the favorable changes in lipid parameters were sustained for three months after the last dose.  Isis is hosting a webcast and key opinion leader panel on Tuesday, November 19, 2013 at 07:15